ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,628Medicare Part D Prescriptions Filled, Including Refills

Rank: 52 out of 198

$633K Total Retail Price of All Prescriptions

Rank: 40 out of 198

418 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 418 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

17% of this provider’s 418 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 7,858 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
SIMVASTATIN 410 330 1 2
FUROSEMIDE 346 290 2 5
HYDROCODONE-ACETAMINOPHEN 337 244 S3 3 8
LEVOTHYROXINE SODIUM 330 254 4 1
AMLODIPINE BESYLATE 314 258 5 4
LISINOPRIL 272 198 6 6
OMEPRAZOLE 237 174 7 3
METOPROLOL TARTRATE 226 173 8 10
WARFARIN SODIUM 214 197 9 7
POTASSIUM CHLORIDE 214 170 9 9
METFORMIN HCL 197 105 11 13
ATORVASTATIN CALCIUM 196 155 12 12
GABAPENTIN 194 123 13 14
TRAMADOL HCL 172 103 14 15
METOPROLOL SUCCINATE 146 106 15 11
CITALOPRAM HBR 134 94 16 20
HYDROCHLOROTHIAZIDE 130 103 17 16
HYDRALAZINE HCL 123 105 18 111
ALENDRONATE SODIUM 109 104 19 21
ATENOLOL 107 82 20 17
DONEPEZIL HCL 105 93 21 28
LOSARTAN POTASSIUM 104 65 22 18
NEXIUM 98 41 23 40
CARVEDILOL 98 70 23 24
TAMSULOSIN HCL 97 66 25 27
ZOLPIDEM TARTRATE 94 76 26 22
NAMENDA 85 72 27 33
FENOFIBRATE 82 57 28 61
MIRTAZAPINE 82 78 28 44
TRAZODONE HCL 79 47 30 50
TRIAMTERENE-HCTZ 78 47 31 32
CRESTOR 76 62 32 26
ENALAPRIL MALEATE 74 69 33 51
CLOPIDOGREL 73 59 34 42
DIGOXIN 70 54 35 43
OXYCODONE-ACETAMINOPHEN 69 49 S2 36 79
ROPINIROLE HCL 69 35 36 74
RANITIDINE HCL 68 53 38 54
MELOXICAM 67 34 39 30
DIOVAN 64 64 40 34
TRICOR 62 46 41 93
GLIPIZIDE 62 45 41 62
ALLOPURINOL 61 47 43 23
BENAZEPRIL HCL 61 52 43 45
ADVAIR DISKUS 60 34 45 47
CIPROFLOXACIN HCL 60 48 45 55
FLUOXETINE HCL 58 21 47 78
FENTANYL 54 37 S2 48 73
CARBIDOPA-LEVODOPA 54 42 48 71
PROAIR HFA 54 41 48 80
JANUVIA 51 36 51 86
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.